The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.
 
Michael Vincent Ortiz
Consulting or Advisory Role - Guidepoint Global
Research Funding - Amgen Astellas BioPharma
 
Julia Lynne Glade Bender
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Bayer (Inst); Eisai (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on a T lympboblastic lymphoma cell line, CUTLL1
Travel, Accommodations, Expenses - Amgen (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Eisai; Merck; Pfizer; SpringWorks Therapeutics
 
Charles G. Minard
Other Relationship - CHEST Journal
 
Xiaowei Liu
No Relationships to Disclose
 
Kristina Z. Denic
No Relationships to Disclose
 
Joel M. Reid
Consulting or Advisory Role - Elucida Oncology
 
Olga Militano
No Relationships to Disclose
 
Alanna J. Church
Honoraria - The Jackson Laboratory
Consulting or Advisory Role - AlphaSights; Bayer; The Jackson Laboratory
 
Alex Kentsis
Consulting or Advisory Role - Blueprint Medicines; Day One Therapeutics; Novartis; Rgenta
 
C. Patrick Reynolds
No Relationships to Disclose
 
Stephan D. Voss
No Relationships to Disclose
 
Elizabeth Fox
No Relationships to Disclose
 
Brenda Weigel
No Relationships to Disclose